28th April 2020
Research has revealed that the signature of metal ions present in urine samples is an accurate indicator of pancreatic ductal adenocarcinoma, one of the deadliest types of cancer.
Read more10th March 2020
The tumour microenvironment: Key to controlling cancer cell growth Research led by Barts Cancer Institute (BCI), Queen Mary University of London, reveals novel insights into the role of the tumour […]
Read more3rd March 2020
Research has identified new genetic features implicated in a type of blood cancer known as familial myeloid leukaemia. The study, published in Nature Communications, offers novel insights into the biology of this inherited cancer, and provides a framework to inform how to more effectively manage at-risk individuals and patients affected by this type of blood malignancy.
Read more27th February 2020
An immune therapy for the most aggressive form of breast cancer can substantially reduce the risk of the disease returning, according to a clinical trial led by Professor Peter Schmid of Barts Cancer Institute, Queen Mary University of London.
Read more12th February 2020
Researchers at Barts Cancer Institute, Queen Mary University of London, have identified a peptide, or protein fragment, taken from the foot-and-mouth-disease virus that targets another protein, called avβ6 (alpha-v-beta-6). This protein is found at high levels on the surface of the majority of pancreatic cancer cells.
Read more27th January 2020
Research led by the Barts Cancer Institute, Queen Mary University of London, has revealed that mouse models of the most common and deadly form of ovarian cancer, high-grade serous ovarian cancer, can effectively replicate the disease in humans. These models provide useful pre-clinical tools that may help to determine which patients are likely to respond to particular treatments.
Read more